Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Accumulated Expenses (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Other Accumulated Expenses for 4 consecutive years, with $777000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 3.32% to $777000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $777000.0 through Dec 2025, up 3.32% year-over-year, with the annual reading at $777000.0 for FY2025, 3.32% up from the prior year.
  • Other Accumulated Expenses hit $777000.0 in Q4 2025 for Taysha Gene Therapies, up from $749000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.6 million in Q1 2022 to a low of $650000.0 in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $899375.0 across 4 years, with a median of $777000.0 in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 56.9% in 2023 and later grew 28.63% in 2024.
  • Year by year, Other Accumulated Expenses stood at $650000.0 in 2022, then increased by 11.23% to $723000.0 in 2023, then rose by 4.01% to $752000.0 in 2024, then increased by 3.32% to $777000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for TSHA at $777000.0 in Q4 2025, $749000.0 in Q3 2025, and $800000.0 in Q2 2025.